GRI Bio (NASDAQ:GRI) Given Sell (E+) Rating at Weiss Ratings

GRI Bio (NASDAQ:GRI)‘s stock had its “sell (e+)” rating reissued by investment analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other brokerages have also recently issued reports on GRI. Ascendiant Capital Markets upped their target price on shares of GRI Bio from $34.00 to $35.00 and gave the company a “buy” rating in a report on Monday, September 22nd. HC Wainwright reaffirmed a “buy” rating on shares of GRI Bio in a report on Wednesday, June 11th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $22.50.

GRI Bio Stock Performance

Shares of GRI stock opened at $1.91 on Wednesday. The firm’s 50-day moving average is $1.62 and its 200-day moving average is $1.75. The stock has a market cap of $4.81 million, a price-to-earnings ratio of -0.17 and a beta of -1.45. GRI Bio has a 52-week low of $1.10 and a 52-week high of $30.43.

GRI Bio (NASDAQ:GRI) last issued its earnings results on Thursday, August 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.31). Sell-side analysts predict that GRI Bio will post -3.04 EPS for the current fiscal year.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.